Akademik Veri Yönetim Sistemi
Journal of Drug Delivery Science and Technology, cilt.100, 2024 (SCI-Expanded)
The current developments such as improving of radionuclides and drug carriers in nuclear medicine has been utilized for cancer diagnosis, prevention and treatment, in other words in theranostics. In radionuclide-based imaging, radionuclides can be conjugated to the nanoparticle and directed to the targeted tissue. Inorganic nanoparticles are capable of imaging and treatment of tumors and have demonstrated unique physicochemical and biological properties. In present study, m-BaTiO3 nanocomposites were prepared by coating biocompatible and nanosized BaTiO3 particles (tra-BaTiO3) with poly (3-acrylamidopropyl) trimethyl-ammonium chloride (pAPTMACl) ionic hydrogel. The prepared m-BaTiO3 nanocomposites were then modified with 99mTcO4- selected as radionuclide and 8-hydroxy-7-iodo-5-quinoline sulfonic acid (SQ) which is a drug used in the treatment of cancer, to form m-BaTiO3-99mTcO4- and m-BaTiO3-SQ radiopharmaceutical nanocomposites, respectively. The characterizations of prepared nanoparticles were carried out with ATR-linked FT-IR and Raman spectroscopy, DLS, zeta potential, TEM, SEM, SEM-Element Mapping analyzes. Radiolabeling studies of m-BaTiO3 nanocomposites were monitored with a radionuclide dose calibrator. The suspension stability of tra-BaTiO3 nanoparticles was increased after the conjugation of 99mTcO4- and SQ molecules. Particle size values ranking found as; m-BaTiO3-99mTcO4- < m-BaTiO3-SQ < m-BaTiO3 < tra-BaTiO3. Zeta potential values were measured as −9.80 ± 1.12 mV, −7.54 ± 4.46 mV, −21.30 ± 0.32 mV, −25.60 ± 0.35 mV for tra-BaTiO3, m-BaTiO3, m-BaTiO3-99mTcO4-, m-BaTiO3-SQ, respectively. The amount of 99mTcO4- attached to the tra-BaTiO3 nanoparticles increased threefold, after coating with the hydrogel. It was observed that 76 % of SQ drug molecules loaded onto m-BaTiO3-SQ nanocomposites was released within 10 h. Herein, we highlighted the design of BaTiO3 nanoparticles with biocompatible and flexible pAPTMACl hydrogel, 99mTc radionuclide, and SQ cancer drug for using of radiopharmaceuticals in cancer imaging and radiotherapy in order to be a pioneer study for our researches in the future.